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ABSTRACT
Background: Measurement of the exhaled nitric oxide fraction (FENO) has been proposed as a useful diag-
nostic test for asthma. However, most of the data concerning the FENO cutoff values for the diagnosis of
asthma have not yet examined using standard procedures. Furthermore, there is no detailed study that investi-
gated the cutoff values that takes into account patient factors that influence the FENO levels.
Methods: FENO was measured in 142 steroid-naive asthmatics and 224 control subjects using an online elec-
trochemical nitric oxide analyzer in accordance with the current guidelines. Subjects without respiratory symp-
toms and normal spirometric parameters were included in the control group. Asthma was diagnosed on the ba-
sis of the presence of significant airway reversibility andor airway hyperresponsiveness during clinical follow
up 6 months after FENO measurements.
Results: FENO was significantly higher in asthmatic patients compared with control subjects (p < 0.01). Based
on all study subjects, the receiver operating characteristic curves indicated that the cutoff value of FENO 22
parts per billion (ppb) was associated with the highest combination of sensitivity (90.8%) and specificity
(83.9%). Multivariate analysis showed allergic rhinitis, current smoking, and asthma were significant factors in-
fluencing the FENO levels. The cutoff values of FENO to discriminate asthma from non-asthma ranged from 18
to 28 ppb depending on rhinitis and smoking status.
Conclusions: The cutoff values presented may be useful for the interpretation of FENO values in the clinical
practice.
KEY WORDS
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oids
ABBREVIATIONS
AUC, area under the curve; BMI, body mass index; FENO, exhaled nitric oxide fraction; ppb, parts per billion;
ROC, receiver operating curve.
INTRODUCTION
The exhaled nitric oxide fraction (FENO) is a useful
marker to assess airway inflammation.1 FENO is ele-
vated in patients with asthma,1,2 and is associated
with airway eosinophilia and airway hyperresponsive-
ness.3-5 Furthermore, FENO has been shown to be
able to discriminate among subjects with asthma and
those without asthma.6-16 Therefore, the measure-
ment of FENO has been proposed as a useful diagnos-
tic test for asthma.1,6-16
The FENO cutoff values for the diagnosis of asthma
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Table　1　Characteristics of the study subjects
Control Asthma
Number (male/female) 224 (98/126) 142 (69/73)
Age (years) 39.4 ± 0.9 41.5 ± 1.4
Height (m) 1.64 ± 0.01 1.64 ± 0.01
Body weight (kg) 58.3 ± 0.8 61.2 ± 1.0
Body mass index (kg/m2) 21.7 ± 0.2 22.7 ± 0.3
Non smoker/Current smoker (n) 172/52 90/52
Non rhinitis/Rhinitis (n) 123/101 48/94
FVC (L) 3.55 ± 0.06 3.61 ± 0.09
%FVC (%) 103.0 ± 0.6 97.7 ± 1.0
FEV1 (L) 3.08 ± 0.05 2.84 ± 0.08*
FEV1% (%) 87.0 ± 0.3 78.3 ± 0.9*
%FEV1 (%) 98.7 ± 0.6 89.1 ± 1.2*
FENO (ppb) 15.9 ± 0.4 47.3 ± 2.9*
Defi nition of abbreviations: FVC, forced expiratory capacity; FEV1, forced expiratory volume in one second; FENO, exhaled nitric oxide 
fraction.
All values are Mean ± SE.*p < 0.01, for between-group comparisons.
Fig.　1　Scatter plot of the exhaled nitric oxide fraction (FENO) 
levels in control subjects and in steroid-naive asthmatic pa-
tients. The horizontal solid bars indicated the mean value for
each group. The best cutoff value to discriminate between 
the groups was obtained from the highest combination of
sensitivity and specifi city and corresponded to 22 ppb.
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have been provided in several previous reports.6-13
However, only a few studies have examined the cutoff
values using current standard procedures in a
steroid-naive population of adults.11-13 In addition, it
has been recognized that FENO is influenced by pa-
tient factors, such as atopy and smoking status.1,13-26
To date, there is a lack of data on the cutoff values re-
lated to patient factors that influence the FENO levels.
In the present study, FENO was measured in
steroid-naive asthmatic patients and control subjects
in accordance with the current guidelines.1 The de-
terminants of the FENO levels were evaluated using a
multivariate model. Furthermore, we also investi-
gated the cutoff values for the diagnosis of asthma ac-
cording to patient factors that influence the FENO lev-
els.
METHODS
STUDY SUBJECTS
Adult subjects with and without respiratory symp-
toms were recruited from the outpatient clinic of
Wakayama Medical University. To avoid the influ-
ence of the cedar pollen season in Japan, the enroll-
ment was performed from May to December 2009. A
detailed interview was performed by physicians. Sub-
jects were excluded if they had a history of lung dis-
eases except for asthma, had a smoking history with
more than 20 pack-years, had had an airway infection
or were taking any form of corticosteroids, β2-
agonists, leukotriene modifiers, and H1-antagonists in
the 4 weeks preceding the study. Recent quitters
were also excluded to stratify the study subjects as
either nonsmokers or current smokers (within the
past 8 weeks). Afterwards, the subjects underwent
measurements for FENO followed by spirometry. Sub-
jects having no respiratory symptoms, no history of
asthma and normal spirometric parameters were in-
cluded in the control group. The diagnosis of asthma
was established after the FENO measurements. We
performed a clinical follow up of 6 months in the sub-
jects with respiratory symptoms (with or without
asthma medication). Chest radiograph and blood ex-
amination were performed at the discretion of the
physician and patients with a clear alternative diagno-
sis were excluded. Asthma was diagnosed on the ba-
Exhaled Nitric Oxide in Asthma Diagnosis
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Table　2　Multivariate model predicting FENO levels in all subjects
Variables Coefficient (95% CI) p value
Intercept 0.83 (0.47; 1.19) <0.0001
Gender (male vs. female) 0.07 (-0.02; 0.17) 0.13
Body mass index (per kg/m2) 0.01 (-0.00; 0.03) 0.09
Smoking (current smoker vs. non smoker) -0.27 (-0.37; -0.17) <0.0001
Rhinitis 0.22 (0.13; 0.31) <0.0001
Asthma 0.94 (0.84; 1.03) <0.0001
Fig.　2　Scatter plot of the exhaled nitric oxide fraction (FENO) levels in control subjects and in asthmatic patients 
according to allergic rhinitis (A) and smoking status (B). The horizontal solid bars indicated the mean value for 
each group.
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sis of the presence of significant airway reversibility
andor airway hyperresponsiveness during the follow
up period. Allergic rhinitis was defined based on com-
patible symptoms (nasal obstruction, rhinorrhea,
sneeze, andor postnasal drainage) in patients with
atopy. Positive specific immunoglobulin E to at least
one common allergen (housedust, mite, cedar, cy-
press, ragweed, cocksfoot, dog, and cat) confirmed
the diagnosis of atopy.
The study was approved by the ethics committee of
Wakayama Medical University and informed consent
was obtained from each subject. Baseline characteris-
tics of the study subjects are presented in Table 1.
STUDY DESIGN
The data obtained from steroid-naive asthmatic pa-
tients and control subjects at the initial testing were
cross-sectionally analyzed for estimating the cutoff
values of FENO.
FENO MEASUREMENTS
FENO was measured by an online electrochemical ni-
tric oxide analyzer (NIOX MINO; Aerocrine AB,
Solna, Sweden) as previously described.26 Measure-
ments of FENO were performed by asking the sub-
jects to empty their lungs and exhale into the device
at a constant flow rate of 50 mLs; the software auto-
matically checks that the breathing manoeuvre is per-
formed according to the current guidelines.1 Re-
peated exhalations were performed to obtain two ac-
ceptable measurements that agreed within 10% devia-
tion, and the average of these two values was regis-
tered. The FENO measurements were performed in
the morning. All subjects had fasted and had not
smoked for at least two hours before the measure-
ments.
STATISTICAL ANALYSIS
Normality assumptions were met for the logarithm of
FENO, the logarithm-transformed value was used in
the analysis and then back-transformed values were
estimated. Comparisons between groups were made
by Mann-Whitney U tests. Among the patient factors,
age, gender, body mass index, smoking status, aller-
gic rhinitis, and asthma were selected, and the factors
influencing the FENO values were analyzed using
multiple linear regression analysis. Multiple stepwise
forward regression analysis was also used. Receiver
operating characteristic (ROC) curves were plotted in
order to estimate the cutoff values for diagnosis. An
optimal cutoff value was obtained from the highest
sum obtained from adding sensitivity and specificity.
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Fig.　3　Receiver operating characteristics (ROC) curves for FENO in the diagnosis 
of asthma according to allergic rhinitis and smoking status. (A) Nonsmoking sub-
jects without rhinitis (99 control subjects and 27 patients with asthma), (B) current 
smoking subjects without rhinitis (28 control subjects and 21 patients with asthma), 
(C) nonsmoking subjects with rhinitis (73 control subjects and 63 patients with 
asthma), (D) current smoking subjects with rhinitis (24 control subjects and 31 pa-
tients with asthma). Data labels represent cutoff values of FENO (arrow), area under 
the curve (AUC), sensitivity and specifi city in each subgroup.
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All data were expressed as mean ± SE and signifi-
cance was defined as a p value of less than 0.05.
RESULTS
The geometric mean FENO was significantly higher in
the asthmatic patients compared with the control sub-
jects (15.9 ppb vs. 47.3 ppb, p < 0.01, Fig. 1). ROC
curves showed the cutoff value of FENO 22 ppb was
associated with the highest combination of sensitivity
(90.8%) and specificity (83.9%) for all study subjects
(Fig. 1). The area under the curve was 0.896.
In the multivariate analysis, asthma and rhinitis
predicted increased FENO levels (coefficient = 0.94,
95% confidence interval [CI]: 0.84-1.03, p < 0.0001,
and coefficient = 0.22, 95% CI: 0.13-0.31, p < 0.0001, re-
spectively). By contrast, current smoking was a sig-
nificant factor that reduced the FENO levels (coeffi-
cient = -0.27, 95% CI: -0.37--0.17, p < 0.0001). The ef-
fects of age, gender, and body mass index on the
FENO levels were not statistically significant (Table
2). Subjects with rhinitis showed significantly higher
levels of FENO compared with subjects without rhini-
tis and the FENO values were significantly lower for
current smokers than for nonsmokers in both groups
(all p < 0.01) (Fig. 2).
Based on the results of the multivariate analysis,
the study subjects were divided into four subgroups
according to allergic rhinitis and smoking status and
the cutoff values for each subgroup were estimated.
The optimal cutoff values of FENO to discriminate be-
tween the subjects with asthma and those without
asthma ranged from 18 to 28 ppb depending on rhini-
tis and smoking status as shown in Figure 3. The dif-
ferent values of sensitivity and specificity for selected
cutoff values of FENO in all subjects and in each sub-
group are listed in Table 3.
Exhaled Nitric Oxide in Asthma Diagnosis
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Table　3　Accuracy of the measurement of FENO in the diagnosis of asthma
FENO 
(ppb)
All Nonsmoking/non-rhinitis Smoking/non-rhinitis Nonsmoking/rhinitis Smoking/rhinitis
Sensitivity
(%)
Specifi city
(%)
Sensitivity
(%)
Specifi city
(%)
Sensitivity
(%)
Specifi city
(%)
Sensitivity
(%)
Specifi city
(%)
Sensitivity
(%)
Specifi city
(%)
14 100.0 57.0 100.0 62.1 100.0 78.3 100.0 42.4 100.0 50.0
16 98.6 67.7 100.0 71.6 100.0 87.0 100.0 53.0 93.3 63.6
18 93.0 75.3 94.1 76.4 85.0 91.3 96.8 57.6 86.7 77.3
20 91.4 78.6 92.3 81.1 80.0 91.3 96.8 68.2 84.4 81.6
22 90.8 83.9 92.3 89.5 70.0 95.7 94.2 69.6 80.0 86.4
24 82.4 88.8 84.6 92.6 60.0 95.7 92.3 72.5 70.0 90.9
26 71.8 91.9 69.2 95.8 55.0 95.7 91.1 73.6 63.3 95.5
28 66.9 93.7 61.5 97.9 50.0 100.0 90.3 77.3 56.7 95.5
30 64.1 95.4 61.5 98.9 50.0 100.0 82.3 81.8 53.3 95.5
DISCUSSION
In the present study, FENO was measured in 142
steroid-naive asthmatic patients and 224 control sub-
jects using the current standard procedures.1 Based
on all study subjects, we have shown that the cutoff
value of FENO to discriminate asthma from non-
asthma was 22 ppb at a flow rate of 50 mLsecond,
with a sensitivity and specificity of 90.8% and 83.9%,
respectively. Allergic rhinitis and current smoking
were significant determinants of the FENO levels. The
optimal cutoff values for the diagnosis of asthma
ranged from 18 to 28 ppb depending on rhinitis and
smoking status. To our knowledge, this is the first
study that investigated the cutoff values that took into
account patient factors that influence the FENO levels.
Although the current standard procedures for the
FENO measurements were recommended in 2005,1
the cutoff values for the diagnosis of asthma have not
yet been established. It is well known that several
technical factors influence the measured FENO level,
including the expiratory flow rate and collection
method. Among these factors, the expiratory flow
rate has been demonstrated to have the most critical
effect, with FENO declining with an increasing expira-
tory flow rate.1 Deykin et al. have reported that the di-
agnostic value of FENO for asthma is not influenced
by either the expiratory flow rate or by collection
method.11 They have also shown that the FENO cutoff
values were inversely related to the expiratory flow
rate.11 However, most of the studies conducted up to
the year 2005 did not include the current standard
procedures, and the cutoff values were not deter-
mined for the recommended expiratory flow rate of
50 mLsecond.6-8 In addition, the FENO levels are re-
lated to inflammation in the asthmatic airway,3,4,27
and treatment with anti-inflammatory drugs such as
corticosteroids results in a marked reduction of these
levels.28 To estimate the FENO cutoff values, we con-
sidered that the use of corticosteroids should be pro-
hibited before the measurements. Although many
studies have shown that FENO is increased in steroid-
naive asthmatics, only a few studies have examined
the cutoff values according to the current guidelines.1
The present study has shown that the cutoff value of
FENO for the diagnosis of asthma was 22 ppb at a flow
rate of 50 mLsecond, which is comparable to the
previously published data.11-13
The measured FENO level is also influenced by pa-
tient factors. Previous studies have shown that there
are several determinants of the FENO levels, such as
age, gender, height, smoking status, atopy, and rhini-
tis.1,13-26 The finding of a higher level of FENO in
atopic subjects has been reported,13-18,22-24 while
chronically reduced levels of FENO have been demon-
strated in current smokers.13,15,18,22,25 By contrast, the
association between FENO and age, gender, and
height is still controversial.1,17-22 Moreover, it has
been reported that the FENO levels in current smok-
ers return to normal levels within 1-8 weeks after
smoking cessation.29,30 We considered these findings
as a justification to subsume never-smokers and ex-
smokers into the same category. In our study, multi-
variate analysis showed that significant confounding
factors are allergic rhinitis and current smoking,
which is consistent with previous reports.13-18,22-25
It has been considered that confounding factors
that influence the FENO levels are important limiting
factors for the implementation of FENO as a diagnos-
tic test for asthma. However, several recent studies
have demonstrated that the diagnostic value of FENO
for asthma is not influenced by either rhinitis or by
smoking.13-16 In the present study, subjects with
rhinitis showed higher levels of FENO compared with
subjects without rhinitis and the FENO values were
lower for current smokers than for nonsmokers in
both controls and asthmatics. However, the FENO lev-
els were significantly higher in the asthma patients
compared with the control subjects irrespective to
rhinitis and smoking status. Kostikas et al. screened a
population of steroid-naive young adults including
current smokers.13 They also reported that allergic
rhinitis and current smoking were determinants of
the FENO levels.13 However, cutoff values that take
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into account these factors were not estimated. Their
study comprised 70 controls and 63 asthmatic pa-
tients, and each group included a small number of
current smokers. In addition, the subjects with con-
comitant asthma and allergic rhinitis were considered
as asthmatics.13 The present study had a large num-
ber of samples that enabled us to estimate the cutoff
values according to patient factors that influence the
FENO levels. We have shown that the lowest cutoff
value was 18 ppb for smoking subjects without aller-
gic rhinitis, and the highest value was 28 ppb for non-
smoking subjects with allergic rhinitis. This analysis
also showed that the area under the curves were over
0.85 in all subgroups, indicating that rhinitis and cur-
rent smoking do not appear to affect the utility of
FENO measurements for the diagnosis of asthma. Al-
though further research is needed to establish the
cutoff values in patients with other factors that influ-
ence the FENO levels, the validity of the cutoff values
according to confounding factors may improve the di-
agnostic value of the FENO measurements for asthma.
In the present study, control subjects were defined
on the basis of detailed interviews and spirometry.
Asymptomatic patients with asthma may be involved
in the control groups. Although the subjects with
asthma-like symptoms were carefully excluded ac-
cording to the guidelines,31 we made no attempt to
validate information by bronchial provocation testing.
This test is sensitive for the diagnosis of asthma but
has limited specificity,31,32 and it will not always be
practical for physicians to perform bronchial provoca-
tion testing before the measurements of FENO. Fur-
thermore, in most of the previous studies, the cutoff
value of FENO was assessed by a different measure-
ment system using a chemiluminescene analyzer.
However, it has been demonstrated that the FENO
values measured by an electrochemical device are re-
liable, reproducible, and in agreement with those of
the chemiluminescene analyzer.9,33,34
In summary, this study has provided further data
on FENO measurements as a diagnostic test for
asthma using the current standard procedures. The
cutoff values presented may be useful for the inter-
pretation of FENO values in the clinical practice.
ACKNOWLEDGEMENTS
We thank Mr. Brent Bell for reading the manuscript,
and also Mr. Satoru Fukinbara for help in statistical
analysis.
This work was supported by grant H21-meneki-
ippan-012 from the Ministry of Health, Labour and
Welfare, Japan.
REFERENCES
1. American Thoracic Society; European Respiratory Soci-
ety. ATSERS recommendations for standardized proce-
dures for the online and offline measurement of exhaled
lower respiratory nitric oxide and nasal nitric oxide. Am J
Respir Crit Care Med 2005;171:912-30.
2. Alving K, Weitzberg E, Lundberg JM. Increased amount
of nitric oxide in exhaled air of asthmatics. Eur Respir J
1993;6:1368-70.
3. Jatakanon A, Sim L, Kharitonov SA, Chung KF, Barnes
PJ. Correlation between exhaled nitric oxide, sputum
eosinophils, and methacholine responsiveness in patients
with mild asthma. Thorax 1998;533:91-5.
4. van den Toorn LM, Overbeek SE, de Jongste JC, Leman
K, Hoogsteden HC, Prins JB. Airway inflammation is pre-
sent during clinical remission of atopic asthma. Am J
Respir Crit Care Med 2001;164:2107-13.
5. Jones SL, Kittelson J, Cowan JO et al. The predictive
value of exhaled nitric oxide measurements in assessing
changes in asthma control. Am J Respir Crit Care Med
2001;164:738-43.
6. Henriksen AH, Lingaas-Holmen T, Sue-Chu M, Bjermer
L. Combined use of exhaled nitric oxide and airway hy-
perresponsiveness in characterizing asthma in a large
population survey. Eur Respir J 2000;15:849-55.
7. Dupont LJ, Demedts MG, Verleden GM. Prospective
evaluation of the validity of exhaled nitric oxide for the di-
agnosis of asthma. Chest 2003;123:751-6.
8. Berkman N, Avital A, Breuer E, Bardach E, Springer C,
Godfrey S. Exhaled nitric oxide in the diagnosis of
asthma: Comparison with bronchial provocation tests.
Thorax 2005;60:383-8.
9. Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric
oxide measurement. Comparison with the “gold stan-
dard” technique. Chest 2007;131:410-4.
10. Schneider A, Tilemann L, Schermer T et al. Diagnosing
asthma in general practice with portable exhaled nitric
oxide measurement. Results of a prospective diagnostic
study. Respir Res 2009;10:15.
11. Deykin A, Massaro F, Drazen JM, Israel E. Exhaled nitric
oxide as a diagnostic test for asthma. Online versus
offline techniques and effect of flow rate. Am J Respir Crit
Care Med 2002;165:1597-601.
12. Smith AD, Cowan JO, Filsell S et al. Diagnosing asthma.
Comparison between exhaled nitric oxide measurements
and conventional tests. Am J Respir Crit Care Med 2004;
169:473-8.
13. Kostikas K, Papaioannou AI, Tanou K, Koutsokera A, Pa-
pala M, Gourgoulianis KI. Portable exhaled nitric oxide as
a screening tool for asthma in young adults during pollen
season. Chest 2008;133:906-13.
14. Heffler E, Guida G, Marsico P et al. Exhaled nitric oxide
as a diagnostic test for asthma in rhinitic patients with
asthmatic symptoms. Respir Med 2006;100:1981-7.
15. Dressel H, de la Motte D, Reichhert J et al. Exhaled nitric
oxide: independent effects of atopy, smoking, respiratory
tract infection, gender and height. Respir Med 2008;102:
962-9.
16. Bommarito L, Bugiani M, Heffler E et al. Exhaled nitric
oxide in a population sample of adults. Respiration 2008;
75:386-92.
17. Olivieri M, Talamini G, Corradi M et al. Reference values
for exhaled nitric oxide (REVENO) study. Respir Res
2006;7:94.
18. Travers J, Marsh S, Aldington S et al. Reference ranges
for exhaled nitric oxide derived from a random commu-
nity survey of adults. Am J Respir Crit Care Med 2007;
176:238-42.
19. Olin AC, Bake B, Toren K. Fraction of exhaled nitric ox-
ide at 50 mLs: reference values for adult lifelong never
smokers. Chest 2007;131:1852-6.
